Microbiome pioneer Seres crushed as lead drug flops in PhII
One of the pioneers in the microbiome R&D world has slammed into a Phase II failure for its lead program. Seres Therapeutics $MCRB says that SER-109 flunked a mid-stage test for reducing the recurrence of Clostridium difficile infection.
SER-109 barely improved on the performance of a placebo in the study, with 44% in the microbiome drug arm seeing a recurrence of CDI, compared to 53% in the sugar pill group. That’s not nearly good enough to qualify as a significant improvement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.